Royalty Pharma RPRX Payments For Milestones
Payments For Milestones at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept rprx:PaymentsForMilestones.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's payments for milestones.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's payments for milestones?
- Royalty Pharma (RPRX) reported payments for milestones of $50M in Q1 2026.
- How has Royalty Pharma's payments for milestones changed year-over-year?
- Royalty Pharma's payments for milestones decreased by 0.0% year-over-year, from $50M to $50M.
- What is the long-term trend for Royalty Pharma's payments for milestones?
- Over 3 years (2021 to 2025), Royalty Pharma's payments for milestones has grown at a 144.3% compound annual growth rate (CAGR), from $18.6M to $271.31M.
- What does payments for milestones mean?
- Cash payments made to partners or developers upon the achievement of specific clinical or regulatory milestones. This is a critical component of royalty-based business models, representing the cost of securing future revenue streams from development-stage assets.